A study for adults with triple negative B-cell ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is for adults with B-cell acute lymphoblastic leukemia (ALL) that does not have three specific gene changes (called BCR-ABL1, TCF3-PBX1, and MLL-AF4). The study will look at people who are newly diagnosed or who have had their cancer come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have B-cell acute lymphoblastic leukemia (ALL).
- Your leukemia cells must not have the BCR-ABL1, TCF3-PBX1, or MLL-AF4 gene changes (this is called 'triple negative').
- You can be recently diagnosed or your cancer may have come back (relapse).
- You agree to allow your medical data to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
Hear when a new Leukemia, Lymphoblastic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.